A Phase II Study to Evaluate the Efficacy, Safety, and Central Nervous System (CNS) Pharmacokinetics of the HER Family Inhibitor Dacomitinib in Progressive Brain Metastases
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2016
Price : $35 *
At a glance
- Drugs Dacomitinib (Primary)
- Indications Brain metastases; Breast cancer; Gastric cancer; Lung cancer; Malignant melanoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 14 Jun 2016 Status changed from recruiting to discontinued due to slow enrollment.
- 24 Apr 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.